GDXJ vs XBI
VanEck Junior Gold Miners ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.77%).
Side-by-side metrics
| Metric | GDXJ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.77% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $7.08B | $10.92B |
YTD return | -0.63% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.17 | 1.01 |
P/E ratio | 12.72 | — |
Last price | $105.88 | $156.41 |
Inception | — | — |
Issuer | VanEck | State Street |
GDXJ top holdings
| AGI.TO | Alamos Gold Inc Class A | 6.52% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.11% |
| CDE | Coeur Mining Inc | 5.89% |
| EDV.L | Endeavour Mining PLC | 5.83% |
| IMG.TO | Iamgold Corp | 5.07% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.62% |
| HL | Hecla Mining Co | 2.26% |
| AG.TO | First Majestic Silver Corp | 2.23% |
| LUG.TO | Lundin Gold Inc | 2.07% |
| BTO.TO | B2Gold Corp | 1.85% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $7.1B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.77%. Its largest holding is Alamos Gold Inc Class A (AGI.TO), which represents 6.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.